CMN Weekly (25 October 2024) - Your Weekly CRISPR...
CMN Weekly
Oct. 25, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Prime Medicine
Main focus: Prime editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: Prime editing
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://primemedicine.com/
Gene editing partnerships: Beam Therapeutics
Prime Medicine is a start-up company that focuses on prime editing. Prime editing is a novel CRISPR-derived gene-editing technology, which was first disclosed in October 2019. Although the company has not revealed its first pre-clinical candidate, it launched with $315M in combined Series A and B funding. The company is co-founded by Professor David R. Liu, who also co-founded Editas Medicine, Beam Therapeutics, Pairwise Plants and Exo Therapeutics.
